Bristol-Myers Squibb Co. (BMY)

47.49
0.67 1.39
NYSE : Health Technology
Prev Close 48.16
Open 48.15
Day Low/High 47.38 / 48.20
52 Wk Low/High 44.30 / 68.22
Volume 12.96M
Avg Volume 18.54M
Exchange NYSE
Shares Outstanding 1.63B
Market Cap 79.86B
EPS 3.00
P/E Ratio 16.25
Div & Yield 1.64 (3.27%)
Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

Dow Closes 400 Points Higher as Wall Street Rebounds on Earnings

Dow Closes 400 Points Higher as Wall Street Rebounds on Earnings

The Dow Jones Industrial Average snaps back solidly Thursday after plunging more than 600 points in the previous session.

Bristol-Myers Beats Q3 Earnings, Boosts Full-Year Outlook on Solid Opdivo Sales

Bristol-Myers Beats Q3 Earnings, Boosts Full-Year Outlook on Solid Opdivo Sales

Bristol-Myers Squibb posts stronger-than-expected third-quarter earnings Thursday and boosts its full-year profit outlook.

Global Stock Sell-Off Wipes Trillions From Markets; US Futures Look To Rebound

Global Stock Sell-Off Wipes Trillions From Markets; US Futures Look To Rebound

Global stocks were awash with red in overnight trading Thursday, loping billions in value from equity markets around Asia following last night's late-trading collapse on Wall Street which has erased year-to-date gains for benchmarks around the world amid concerns over weakening U.S. earnings growth, rising geo-political tensions and the unknown outcome of trade disputes between Washington and its major economic partners.

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

It becomes difficult for me to tell you where to run in these markets...

Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze® Technology

Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze® Technology

SAN DIEGO, Oct. 25, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Bristol-Myers Squibb Reports Third Quarter Financial Results

Bristol-Myers Squibb Reports Third Quarter Financial Results

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the third quarter of 2018 which were highlighted by strong sales and operating performance along with key regulatory and clinical milestones across the portfolio.

Jim Cramer: Avoid the Naked CEOs When the Tide Goes Out

Jim Cramer: Avoid the Naked CEOs When the Tide Goes Out

There is clear divergence between the best and the worst performers in each sector this earnings season.

Mirati Shares Fall After Cancer Trial Progress Report

Mirati Shares Fall After Cancer Trial Progress Report

Shares of Mirati Therapeutics fell Monday after the drug developer released a progress report of an early stage clinical trial of its lung cancer drug used in conjunction with a Bristol-Myers Squibb Co. medication.

Bristol-Myers Slides After FDA Delays Marketing Approval for Cancer Therapy

Bristol-Myers Slides After FDA Delays Marketing Approval for Cancer Therapy

Bristol-Myers Squibb fall sharply after the U.S. Food & Drug Administration extends the approval date for a combination-drug treatment for lung cancer patients.

Dow Trades Lower After Momentum From China Rally Fades, Nasdaq Rises

Dow Trades Lower After Momentum From China Rally Fades, Nasdaq Rises

Stocks are mixed after rising earlier in the session following a rally in China that saw stocks soar to their biggest single-day gain in nearly three years.

Opdivo (nivolumab) In Combination With Yervoy (ipilimumab) Results In Significantly Longer Treatment-Free Survival In Patients With Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma

Opdivo (nivolumab) In Combination With Yervoy (ipilimumab) Results In Significantly Longer Treatment-Free Survival In Patients With Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma

Bristol-Myers Squibb Company (NYSE:BMY) today announced the results of a new analysis from the Phase 3 CheckMate -214 study, demonstrating that therapy with Opdivo (nivolumab) plus Yervoy (ipilimumab) in patients with previously untreated advanced or...

Opdivo (nivolumab) In Combination With Yervoy (ipilimumab) Demonstrates Durable Four-Year Survival Benefits In Patients With Advanced Melanoma

Opdivo (nivolumab) In Combination With Yervoy (ipilimumab) Demonstrates Durable Four-Year Survival Benefits In Patients With Advanced Melanoma

Bristol-Myers Squibb Company (NYSE: BMY) today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of...

Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Durable Clinical Benefit In Previously Untreated Patients With MSI-H Or DMMR Metastatic Colorectal Cancer

Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Durable Clinical Benefit In Previously Untreated Patients With MSI-H Or DMMR Metastatic Colorectal Cancer

Bristol-Myers Squibb Company (NYSE: BMY) today announced new data from a cohort of the CheckMate -142 study in which Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) demonstrated durable clinical benefit as a first-line treatment in patients with...

Opdivo (nivolumab) In Combination With Yervoy (ipilimumab) Shows Promising Results In Patients With Advanced Form Of Bladder Cancer

Opdivo (nivolumab) In Combination With Yervoy (ipilimumab) Shows Promising Results In Patients With Advanced Form Of Bladder Cancer

Bristol-Myers Squibb Company (NYSE: BMY) today announced follow-up data evaluating Opdivo (nivolumab) monotherapy and Opdivo in combination with Yervoy (ipilimumab) in patients with platinum-pretreated metastatic urothelial carcinoma (mUC).

Bristol-Myers Squibb Provides Update On The Ongoing Regulatory Review Of Opdivo Plus Low-Dose Yervoy In First-Line Lung Cancer Patients With Tumor Mutational Burden ≥10 Mut/Mb

Bristol-Myers Squibb Provides Update On The Ongoing Regulatory Review Of Opdivo Plus Low-Dose Yervoy In First-Line Lung Cancer Patients With Tumor Mutational Burden ≥10 Mut/Mb

Bristol-Myers Squibb Company (NYSE:BMY) announced updates regarding regulatory actions by health authorities in the United States (U.

Bristol-Myers Squibb To Showcase Immunoscience Research And Biomarker-Guided Treatment Approaches At The 2018 American College Of Rheumatology And Association Of Rheumatology Health Professionals Annual Meeting

Bristol-Myers Squibb To Showcase Immunoscience Research And Biomarker-Guided Treatment Approaches At The 2018 American College Of Rheumatology And Association Of Rheumatology Health Professionals Annual Meeting

Bristol-Myers Squibb Company (NYSE:BMY) today announced that 28 abstracts related to ORENCIA ® (abatacept) and the Company's immunoscience pipeline will be presented at the 2018 American College of Rheumatology and Association of Rheumatology Health...

Bristol-Myers Squibb Announces Phase 3 CheckMate -331 Study Does Not Meet Primary Endpoint Of Overall Survival With Opdivo Versus Chemotherapy In Patients With Previously Treated Relapsed Small Cell Lung Cancer

Bristol-Myers Squibb Announces Phase 3 CheckMate -331 Study Does Not Meet Primary Endpoint Of Overall Survival With Opdivo Versus Chemotherapy In Patients With Previously Treated Relapsed Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) today announced topline results from the Phase 3 CheckMate -331 study evaluating Opdivo (nivolumab) versus the current standard of care, topotecan or amrubicin (where approved), in patients with small cell lung...

Bristol-Myers Squibb And Compugen Announce Clinical Collaboration To Evaluate Therapeutic Regimen In Advanced Solid Tumors

Bristol-Myers Squibb And Compugen Announce Clinical Collaboration To Evaluate Therapeutic Regimen In Advanced Solid Tumors

NEW YORK and HOLON, Israel, Oct. 11, 2018 /PRNewswire/ --  Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of...

Bristol-Myers Squibb And Compugen Announce Clinical Collaboration To Evaluate Therapeutic Regimen In Advanced Solid Tumors

Bristol-Myers Squibb And Compugen Announce Clinical Collaboration To Evaluate Therapeutic Regimen In Advanced Solid Tumors

Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen's COM701, an investigational anti-PVRIG antibody, in...

Biotech and Broadway Come Together to Fight Cancer

Biotech and Broadway Come Together to Fight Cancer

Cancer affects all of us. But the Damon Runyon Cancer Research Foundation has invested $355 million (and counting) in research to fight it. We spent time with its incoming CEO to hear about her journey and how immunotherapies are taking the lead.

Consider These Diagnostic Testing Firms

Consider These Diagnostic Testing Firms

Diagnostic firms can have an advantage of recurring revenue streams.

European Medicines Agency Validates Bristol-Myers Squibb's Application For Empliciti (elotuzumab) Plus Pomalidomide And Low-Dose Dexamethasone In Patients With Multiple Myeloma

European Medicines Agency Validates Bristol-Myers Squibb's Application For Empliciti (elotuzumab) Plus Pomalidomide And Low-Dose Dexamethasone In Patients With Multiple Myeloma

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Medicines Agency (EMA) has validated the Company's type II variation application for Empliciti (elotuzumab) in combination with pomalidomide and low-dose dexamethasone (EPd) for...

Bristol-Myers Squibb Announces Dividend

Bristol-Myers Squibb Announces Dividend

The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of forty cents ($0.

Bristol-Myers Squibb's Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance In Patients With Moderate To Severe Plaque Psoriasis In Phase 2 Trial

Bristol-Myers Squibb's Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance In Patients With Moderate To Severe Plaque Psoriasis In Phase 2 Trial

Bristol-Myers Squibb Company (NYSE:BMY) today announced results from a Phase 2 study of BMS-986165, an investigational oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis.

Bristol-Myers Squibb To Take Part In Morgan Stanley Global Health Care Conference

Bristol-Myers Squibb To Take Part In Morgan Stanley Global Health Care Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Morgan Stanley 2018 Global Health Care Conference on Thursday, September 13, 2018, in New York.

Bristol-Myers Squibb To Announce Results For Third Quarter 2018 On October 25

Bristol-Myers Squibb To Announce Results For Third Quarter 2018 On October 25

Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter of 2018 on Thursday, October 25, 2018.

We Are Riding For Patients

We Are Riding For Patients

Today, for the fifth year in a row, Bristol-Myers Squibb Company (NYSE:BMY) is launching Coast 2 Coast 4 Cancer, a nearly month-long cross-country bike ride to raise money for cancer research.

(Photo: Business Wire)

(Photo: Business Wire)

Bristol-Myers Squibb Company (NYSE:BMY) today announced that Christopher Boerner, Ph.

TheStreet Quant Rating: C+ (Hold)